Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:45:20.942Z.
Calculation as of: 2026-10-06T13:45:20.942Z.
Quote observation: 2026-10-06T13:45:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Aclaris Therapeutics, Inc.
Market Cap
$580.12M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
Price/OCF Ratio
N/A
TTM Avg
14.09
3Y Avg
14.09
5Y Avg
14.09
Market Cap
$559.96M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$554.05M
Price/OCF Ratio
N/A
TTM Avg
41.16
3Y Avg
40.24
5Y Avg
16.59
Market Cap
$590.58M
Price/OCF Ratio
79.72
TTM Avg
75.01
3Y Avg
75.01
5Y Avg
75.01
Market Cap
$595.08M
Price/OCF Ratio
3.21
TTM Avg
7.03
3Y Avg
5.98
5Y Avg
6.64
Market Cap
$546.13M
Price/OCF Ratio
27.88
TTM Avg
30.64
3Y Avg
39.07
5Y Avg
39.07
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $580.12M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 14.09 | 14.09 | 14.09 |
| CorMedix Inc. (CRMD)vs › | $564.85M | 2.22 | 8.23 | 11.13 | 11.13 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $559.96M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $554.05M | N/A | 41.16 | 40.24 | 16.59 |
| OrthoPediatrics Corp. (KIDS)vs › | $590.58M | 79.72 | 75.01 | 75.01 | 75.01 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $595.08M | 3.21 | 7.03 | 5.98 | 6.64 |
| Delcath Systems, Inc. (DCTH)vs › | $546.13M | 27.88 | 30.64 | 39.07 | 39.07 |
| Immix Biopharma, Inc. (IMMX)vs › | $540.75M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $538.28M | 392.90 | 294.84 | 294.84 | 294.84 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
